Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 391OTHER 309NIH 64OTHER_GOV 6UNKNOWN 3NETWORK 2INDIV 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 3Stomach Neoplasms 2Rectal Neoplasms 2Neoplasms 2Advanced Cancer 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Lymphoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Tumor of Digestive Tract or Urinary System 1Adenocarcinoma 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × UNKNOWN × Melanoma × Clear all
NCT02346955 2020-08-27

MK-6018-001

KitovPharma

Phase 1 Terminated
27 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00399113 2011-07-14

Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

PainT

Phase 1 Completed
12 enrolled
Dermatologic

Melanoma

NCT00734188 2011-07-14

Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

PainT

Phase 1 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡